Drug Discovery
Biologics and Antibody Engineering
Generate novel antibody sequences and biologics candidates with predicted binding specificity, developability, and immunogenicity profiles.
The Challenge
Why Biologics and Antibody Engineering needs a new approach to generation
Antibody therapeutics address targets inaccessible to small molecules, but discovering antibodies with the right combination of affinity, specificity, stability, and low immunogenicity requires searching an astronomical sequence space. Traditional antibody discovery relies on animal immunization or phage display — methods that sample the space stochastically and produce leads requiring extensive optimization. The sequence-to-function relationship for antibodies is complex and poorly mapped, making rational design extremely difficult with existing tools.
Current computational antibody design methods use homology modeling, molecular dynamics, and structure-based mutagenesis to optimize known antibody frameworks. Generative models trained on antibody sequence databases produce plausible sequences but cannot reliably enforce the simultaneous constraints on binding, stability, expression yield, and immunogenicity that determine clinical success. Most generated sequences require extensive experimental optimization before they become viable drug candidates.
The MatterSpace Approach
How MatterSpace generates for biologics and antibody engineering
MatterSpace Pharma generates antibody sequences where binding specificity, developability, and immunogenicity are co-optimized through constraint-based generation. Specify the target epitope, affinity requirements, cross-reactivity restrictions, and developability criteria, and Pharma constructs CDR sequences within validated framework contexts that satisfy all constraints simultaneously.
The Biologics domain pack encodes antibody structure-function relationships, immunogenicity prediction models, and developability scoring for expression, aggregation, and viscosity. Users define the therapeutic specification and Pharma generates ranked antibody sequence candidates with predicted properties and recommended validation experiments.
Constraint-Based Generation
Specify what the output must satisfy. MatterSpace constructs candidates that meet all constraints simultaneously.
Valid by Construction
Every output satisfies physical laws, stability criteria, and domain constraints — no post-hoc filtering needed.
MatterSpace Pharma
Powered by a domain-specific generation engine with physics-aware priors and adaptive dynamics control.
Generation Output
What MatterSpace generates
- Novel antibody CDR sequences with predicted binding affinities
- Full-length antibody candidates with developability scores
- Humanized sequence variants with immunogenicity predictions
- Bispecific antibody architectures for dual-target engagement
Key Differentiators
Why MatterSpace is different
MatterSpace Pharma generates antibody candidates with simultaneous optimization across affinity, specificity, stability, and immunogenicity — resolving the sequential optimization bottleneck that makes conventional antibody engineering campaigns take years. The system generates novel CDR sequences that go beyond humanization of existing leads, accessing antibody solutions that stochastic discovery methods would require impractical library sizes to find.
Same sector
Related industries
Small Molecule Drug Design
Generate novel small molecule candidates optimized for target binding affinity, selectivity, and drug-likeness from a therapeutic specification.
ViewADMET Optimization
Generate molecular modifications that optimize absorption, distribution, metabolism, excretion, and toxicity profiles while preserving target activity.
ViewPeptide and Macrocycle Design
Generate novel peptide sequences and macrocyclic structures with target binding affinity, proteolytic stability, and cell permeability for challenging therapeutic targets.
ViewGet started
Start generating with MatterSpace
Whether you are exploring biologics and antibody engineering for the first time or scaling an existing research programme, MatterSpace generates novel candidates that satisfy your constraints by construction.
Contact us